Real-World data reveals how prostate cancer patients fare on new targeted radiation therapy
NCT ID NCT07477756
First seen Mar 19, 2026 · Last updated May 13, 2026 · Updated 7 times
Summary
This study examined over 1,200 men with advanced prostate cancer who received a radioactive drug called Lutetium-177. Researchers wanted to see what types of patients get this treatment, how many doses they receive, and how their PSA levels change. The goal was to understand how the drug works outside of clinical trials, in real-world medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.